Anne Luetkemeyer
University of California, San Francisco
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anne Luetkemeyer as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:02 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT03980223 · Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With MenUniversity of California, San Francisco · completed · Gonorrhea, Chlamydia, Syphilis · principal investigator
- Ph4NCT02206932 · A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis CUniversity of California, San Francisco · withdrawn · Hepatitis C, Chronic, HIV CDC Category A1 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- The Doxy-PEP Impact Study: a multi-city US longitudinal cohort to evaluate doxy-PEP field effectiveness, investigate associated antimicrobial resistance, and establish doxy-PEP to need ratiosR01AI181732 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2024 to 2026 · $1,480,679 awarded in 2026Same name and institution; not confirmed by an ID
- Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with menR01AI143439 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2019 to 2023 · $1,412,385 awarded in 2023Grant number is on one of their registry trials
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:02 UTC. The ranking covers the 200 most relevant of 46 PubMed records, and a shared surname and initials can bring in a namesake. All 46 on PubMed
- Remdesivir for the Treatment of Covid-19 - Final Report.N Engl J Med · 20205,332 citationsRCR 287.3
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.N Engl J Med · 20211,413 citationsRCR 83.9
- Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.N Engl J Med · 2011435 citationsRCR 14.1
- 406 citationsRCR 59.9
- Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.N Engl J Med · 2015379 citationsRCR 14.1
- Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.N Engl J Med · 2015336 citationsRCR 12.9
- Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.Ann Intern Med · 2016314 citationsRCR 13.8
- 207 citationsRCR 7.2
- Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals.Am J Respir Crit Care Med · 2007166 citationsRCR 4.9
- Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.Lancet Respir Med · 2021145 citationsRCR 6.9